Seeking Alpha1mon
Mersana falls after early-stage trial data for lead cancer therapy
Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
ETF Daily News1mon
Mersana Therapeutics Announces Positive Initial Clinical Data and FDA Fast Track Designation for Emiltatug Ledadotin (XMT-1660)
Mersana Therapeutics, Inc. recently disclosed encouraging updates in a Form 8-K report filed with the Securities and Exchange Commission. The company unveiled positive initial clinical data from ...
ETF Daily News1mon
Mersana Therapeutics’ (MRSN) Outperform Rating Reiterated at Wedbush
Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...
Business Insider1mon
Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility
Despite a significant drop in Mersana’s stock price, Zelin views this as an exaggerated reaction to certain adverse events and believes the therapeutic efficacy of Emi-Le provides a compelling ...
AOL1mon
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...